In vivo modulation of immune response to vaccination
04 February 2021
•
OA18
•
15:00
>
16:00
•
In vivo modulation of immune response to vaccination
•
Live channel 1
15:00
•
OA18.01
•
Early Vaccine-Induced V1V2 Antibody Responses in Four Pox-Protein Public Private Partnership (P5) HIV Vaccine Trials
See abstract
15:08
•
OA18.02
•
Similar antibody responses to subtype C ALVAC-HIV/gp120 vaccine regimens using different adjuvants (MF59 vs. alum) but enhanced response rates and magnitude when ALVAC-HIV and gp120 were co-administered
See abstract
15:16
•
OA18.03
•
Alum-adjuvanted protein administered in combination with ALVAC-HIV downregulates early serum cytokine responses to the vaccine whereas MF59 enhances the early cytokine burst
See abstract
15:24
•
OA18.04
•
Heterologous prime boost immunisations with improved DNA, MVA and protein HIV-1 subtype C vaccines elicit Tier 2 neutralising antibodies in a Chinese rhesus monkey model
See abstract
15:32
•
OA18.05LB
•
Multivalent antigen presentation increases the antibody binding breadth and neutralizing potency upon the immunization with a self-assembling HIV env vaccine
See abstract
15:40
•
OA18.06
•
Live Q&A
See abstract
|